Compare JF & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | JF | PPCB |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | Hong Kong | Australia |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 18.1M |
| IPO Year | 2017 | 2011 |
| Metric | JF | PPCB |
|---|---|---|
| Price | $0.90 | $1.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.6K | ★ 34.1K |
| Earning Date | 12-01-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $0.06 |
| 52 Week High | $1.19 | $6.79 |
| Indicator | JF | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 45.09 | 59.23 |
| Support Level | $0.81 | $1.61 |
| Resistance Level | $1.03 | $1.99 |
| Average True Range (ATR) | 0.04 | 0.15 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 0.13 | 43.63 |
J and Friends Holdings Ltd providing merchant digitalization and commerce-enablement solutions to small and medium enterprises (SME). Its solutions feature critical functionality that SMEs need to engage with consumers, manage their operations, accept payments, and grow their business. Such solutions empower single- and multi-location retailers, restaurants, and other SMEs to compete successfully in an omni-channel market environment by engaging with consumers across online, mobile, and physical channels. The group conducts all of its current operations in Australia and generates revenues from continuing operations are derived from within Australia.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.